Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome Original paper
-
Dr. Umar
Read MoreClinical Pharmacist and Clinical Pharmacy Master’s candidate focused on antibiotic stewardship, AI-driven pharmacy practice, and research that strengthens safe and effective medication use. Experience spans digital health research with Bloomsbury Health (London), pharmacovigilance in patient support programs, and behavioral approaches to mental health care. Published work includes studies on antibiotic use and awareness, AI applications in medicine, postpartum depression management, and patient safety reporting. Developer of an AI-based clinical decision support system designed to enhance antimicrobial stewardship and optimize therapeutic outcomes.
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
What was studied
This study examined dysbiosis of the saliva microbiome in polycystic ovary syndrome (PCOS), with emphasis on how microbiota behavior—including diurnal oscillation—differs between affected and healthy women. The focus keyphrase saliva microbiome in PCOS is central here because the investigators explored microbial signatures, taxonomic shifts, and predicted functional changes across four time points over 24 hours. Using 16S rRNA gene sequencing, the researchers mapped salivary and fecal bacterial communities to determine whether PCOS alters microbial diversity, abundance, rhythmicity, and pathway-level characteristics. Their working hypothesis was that circadian oscillations known to occur in healthy salivary microbiota are disrupted in PCOS, which could contribute to local and systemic disease risk.
Who was studied
The cohort included 10 women with PCOS diagnosed by Rotterdam criteria and 10 healthy controls, ages 18–45, all of whom followed standardized dietary guidelines and avoided antibiotics, probiotics, smoking, alcohol, and oral disease that might confound oral microbial signatures. Four saliva samples (ZT0, ZT6, ZT12, ZT18) and one fecal sample per participant were collected under controlled inpatient conditions. The groups were comparable in age and BMI, although PCOS participants exhibited characteristic hormonal alterations, including higher total testosterone and LH/FSH ratios.
Most important findings
PCOS markedly altered the saliva microbiome at every time point. Alpha diversity was significantly reduced at ZT0, while beta-diversity analyses showed distinct clustering between PCOS and controls at ZT0 and ZT18. Across pages 3–5, figures show consistent enrichment of the phylum Fusobacteria and genus Fusobacterium in PCOS saliva at all time points, a microbe linked to inflammation, periodontal disease, metabolic dysfunction, and obesity. LEfSe analysis revealed decreased Actinobacteria and Leptotrichia at multiple time points, alongside gains in taxa such as Gracilibacteria and Clostridiales, depending on the sampling period. These patterns suggest microbial instability, loss of beneficial commensals, and potential overrepresentation of inflammatory contributors. Functional predictions showed recurring upregulation of methane metabolism and downregulation of chaperones, folding catalysts, membrane structural molecules, and secretion systems—changes suggesting impaired microbial protein handling and increased fermentation potential. Several pathways fluctuated rhythmically in healthy controls but not in PCOS, supporting disrupted microbial chronobiology. Diurnal oscillation analysis revealed that taxa such as Proteobacteria, Bacteroidetes, Actinobacteria, Lactobacillales, Prevotellaceae, and Bacteroidales displayed significant rhythmicity in controls but largely lost rhythmic patterns in PCOS. Fecal microbiota, by contrast, showed no consistent PCOS-specific signature, underscoring compartment-specific dysbiosis.
Key implications
Disrupted diurnal rhythm of salivary microbiota in PCOS suggests a chronobiological dimension to disease pathophysiology. Increased Fusobacteria and reduced beneficial taxa may contribute to chronic inflammation, periodontal disease risk, and metabolic dysfunction. The findings highlight the relevance of oral microbiome assessment—and timing of sampling—for understanding systemic features of PCOS and refining microbiome-based clinical tools.
Citation
Li N, Li Y, Qian C, et al. Dysbiosis of the saliva microbiome in patients with polycystic ovary syndrome.Front Cell Infect Microbiol. 2021;10:624504. doi:10.3389/fcimb.2020.624504
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age, characterized by irregular menstrual cycles, hyperandrogenism, and insulin resistance. It is often associated with metabolic dysfunctions and inflammation, leading to fertility issues and increased risk of type 2 diabetes and cardiovascular disease.